🔗 Share this article

As America undertakes sweeping revisions to its immunization guidelines, a particular individual appears in a surprising turn: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about coronavirus vaccines during the pandemic and has zeroed in on possible deaths after Covid vaccination in her recent tenure at the Food and Drug Administration.

Scheduled Overhauls to Childhood Immunization Schedule

Agency leaders were set to announce radical revisions to the childhood vaccine schedule in December, bringing the US with Denmark’s immunization schedule, sources say – a significant shift that would put the US at odds with many the international standard with little proof for improved outcomes. The planned update has been postponed until the new year.

Instead of the director of the vaccine center, Høeg is set to address the audience at the event. She was just designated interim head of the FDA’s drug evaluation center, the fifth individual to lead the division this year.

Consolidating Power at the Agency

This interim role could signify a strengthened alliance between the drug and vaccine branches as Dr. Høeg and Prasad strengthen their influence at the FDA – and it signals a greater focus upon dismantling long-standing immunizations at the FDA.

The new acting director has frequently advocated for ending some childhood immunization guidelines in the US so as to align more similar to Denmark, a society with universal health coverage and a number of inhabitants roughly the population of the state of Wisconsin.

To date comments, she has kept her attention on vaccines – typically the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Qualifications

The appointee has no obvious track record in medication creation, oversight or leadership, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for running the CDER, said Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in leading a large organization. She lacks background in industry regulation.”

Past heads of the center would “be deeply familiar with regulatory frameworks and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she lacks the sort of resume that previous people who headed CBER have had.”

This division has an immense portfolio at the FDA, the former commissioner pointed out.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office approves thousands of generic drugs. There is also a biosimilars program, non-prescription drug unit and more, and every single one need to be supervised,” she noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a major administrative component to the job, which oversees in excess of 5,000 staff members. “It is a huge management job, if you do it right,” Woodcock added.

Official Statement and Contentious Policies

When asked about questions about Høeg’s fitness for the role and whether this appointment indicates more teamwork among FDA leaders on vaccines, a spokesperson said that the “questions rely on incorrect presumptions”.

“Her experience is consistent with the duties of her position,” the representative said, noting the time Dr. Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg inherits the commissioner’s recently launched expedited review system, a disputed rapid therapy clearance system that allegedly worried her preceding directors. “How are these drugs being picked for this expedited pathway? Who makes the decisions?” Dr. Howard asked. “There’s a lot of lack of transparency occurring at the FDA right now.”

Overall, he remarked, “the agency appears to be shifting towards less stringent rules of most medications, with the exception of immunizations.”

Public Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if troubling, history, some experts observe. She authored a research paper using non-validated crowd-sourced reports to estimate the incidence of heart inflammation after Covid immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to imply Covid vaccinations are more dangerous than they are.

Part of her “wish list” for the new administration encompassed revising rules for new vaccines and ending “optional” vaccines, she stated following the vote on a online show. At the FDA, Dr. Høeg has according to sources proposed barring teenage boys from getting Covid vaccines.

“She is an thorough ideologue who commences with her conclusions and reverse-engineers to retrofit the evidence in a very deceptive, dishonest manner,” Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|